Inspired by the successful television series, the UCL School of Pharmacy has organised this clever and well-attended event where UCL scientists presented their small molecule therapeutics idea to a panel of seasoned pharma experts and investors, in front of a public of scientists and company representatives. We couldn’t resist the temptation to pitch our Virology Research Services, and although VRS is not quite a small molecule, it was clearly exciting enough to win the third prize from the public! Thank you!
Recents Posts
How to design an antiviral assay
Things to consider when designing the experiment When a new compound, antibody or test article is being tested for antiviral activity, there are several aspects to consider when designing the experiment. The choice of virus, cells and readout is important, but so are...
Five Questions to Ask Before Starting an Antiviral Study
Starting an antiviral programme is exciting. Whether you are developing a novel antiviral, validating a new platform technology, testing a disinfectant, or evaluating the neutralising activity of an antibody, the temptation is to jump straight to the experimental...
How to Choose the Right In Vitro Model for an Antiviral Study
Discussions on antiviral testing often focus on viral strains, compound administration, and assay parameters. Yet one of the most important decisions has already been made behind the scenes: selecting the most appropriate in vitro model. At VRS, our standard antiviral...
When it comes to viruses, we know our stuff!
Subscribe

